After a significant rebound in 2023 and in 2024, Grifols is now entering into a phase of slower earnings improvement. Underlying growth was still solid in 2025 (+9% for revenues and +11% for adjusted EBITDA excluding the IRA and currency impacts) but external factors weighed on results (they were up by +4% and +3% respectively on a reported basis). The company is guiding for 5% to 9% adjusted EBITDA growth on constant FX this year and is not providing any revenue guidance, apart from saying that...
After a significant rebound in 2023 and in 2024, Grifols is now entering into a phase of slower earnings improvement. Underlying growth was still solid in 2025 (+9% for revenues and +11% for adjusted EBITDA excluding the IRA and currency impacts) but external factors weighed on results (they were up by +4% and +3% respectively on a reported basis). The company is guiding for 5% to 9% adjusted EBITDA growth on constant FX this year and is not providing any revenue guidance, apart from saying that...
A director at Reply Spa bought 2,000 shares at 83.848EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
ABN AMRO: Dutch State stake (NLFI) now below 25%. ASML: Preview 1Q26 - ongoing momentum. D'Ieteren: PHE raises financing to acquire majority stake in two Spanish distributors. Dutch pension buyouts: Athora registers one more (small) deal. Orange Belgium: Nethys does not exercise put option on its remaining stake. Vår Energi: Looking ahead to 2Q26
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.